TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS REPORT BY THE DECISION SUPPORT UNIT Stephen Palmer, Mark Sculpher

Source URL: www.nicedsu.org.uk

NOVEMBER 2015 TABLE OF CONTENTS INTRODUCTION

Source URL: www.abirisk.eu

• Medicine
• Clinical medicine
• Immunology
• Immunosuppressants
• RTT
• Rheumatology
• Orphan drugs
• Specialty drugs
• Tocilizumab
• Autoimmunity
• Rituximab
• Rheumatoid arthritis

TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Source URL: www.nicedsu.org.uk

• Health economics
• Healthcare quality
• Immunosuppressants
• Orphan drugs
• Costs
• Disease-modifying antirheumatic drug
• Tocilizumab
• Rituximab
• Quality-adjusted life year
• Rheumatoid arthritis
• Etanercept
• TNF inhibitor

JULY 2016 TABLE OF CONTENTS INTRODUCTION

Source URL: www.abirisk.eu

• Immunosuppressants
• Monoclonal antibodies
• Immunology
• Biotechnology
• Immune system
• TNF inhibitor
• Infliximab
• Tocilizumab
• Adalimumab
• Tumor necrosis factor alpha
• Natalizumab
• Etanercept

TABLE OF CONTENTS INTRODUCTION 2

Source URL: www.abirisk.eu

• Monoclonal antibodies
• Immunosuppressants
• Immunology
• Biotechnology
• Immune system
• Adalimumab
• Tocilizumab
• Infliximab
• Monoclonal antibody therapy
• Disease-modifying antirheumatic drug
• TNF inhibitor
• Rheumatology

Important Safety Information for Infectious Disease Specialists About Potential Risks of Infections With ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food

Source URL: www.actemrahcp.com

Important Safety Information for Emergency Medicine Physicians About Potential Risks of Infection and Gastrointestinal Perforation With ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist tha

Source URL: www.actemrahcp.com

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA® (tocilizumab) Injection, for

Source URL: www.accessdata.fda.gov

Important Safety Information for Rheumatologists About Risks in Patients Receiving ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food and Drug Administrati

Source URL: www.actemrahcp.com

Important Safety Information for Gastroenterologists and Hepatologists About Potential Risks of Gastrointestinal Perforation and Transaminase Elevations With ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) r

Source URL: www.actemrahcp.com